RecruitingPhase 3NCT06463379
The Efficacy of Intravenous Pulse in Attaining Remission in Refractory Juvenile Idiopathic Arthritis
Sponsor
Sohag University
Enrollment
215 participants
Start Date
May 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Interventional phase 3 study aiming to unravel the value of pulse steroids in achieving remission or low disease activity in refractory active JIA
Eligibility
Min Age: 2 YearsMax Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Solumedrol for people with refractory juvenile idiopathic arthritis (despite 2 dmards still active). The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Years to 18 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSolumedrol
2 days pulse steroid injection 125 mg methylrednisolone
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06463379